

WEHI-539 hydrochloride

| Cat. No.: | A8634 |
|-----------|----------------|
| CAS No.: | 2070018-33-4 |
| Formula: | C31H30CIN5O3S2 |
| M.Wt: | 620.18 |
| Synonyms: | |
| Target: | Apoptosis |
| Pathway: | Bcl-xL |
| Storage: | Store at -20°C |
| | |

Solvent & Solubility

≥28.55mg/mL in DMSO

| | | Mass | | | |
|----------|-----------------|---------------|-----------|-----------|------------|
| | . . | Solvent | 1mg | 5mg | 10mg |
| In Vitro | Preparing | Concentration | | | |
| | Stock Solutions | 1 mM | 1.6124 mL | 8.0622 mL | 16.1244 mL |
| | | 5 mM | 0.3225 mL | 1.6124 mL | 3.2249 mL |
| | 0 | 10 mM | 0.1612 mL | 0.8062 mL | 1.6124 mL |

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

| | & | Target |
|------|--------|--------|
| 1050 | \sim | rargot |

| | Cell Viability Assay | al ^Q |
|----------|----------------------|---|
| | Cell Line: | Human colon cancer cell |
| In Vitro | Preparation method: | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
| | Reacting conditions: | 1 μM, 24h |
| | Applications: | Limiting dilution analysis with CSCs that were pre-treated with ABT-737, |
| | | 1 www.apexbt.com |

| | | ABT-199 or WEHI-539 revealed that ABT-737 and WEHI-539 both were |
|---------|-------------------|---|
| | | sufficient to decrease clonogenic capacity, whereas ABT-199 did not affect |
| | | clonogenic growth. As WEHI-539 is selective for BCLXL, this points to a |
| | | dependency of CSCs on BCLXL for survival. Importantly, ABT-737- or |
| | | WEHI-539-induced loss of clonogenicity could be restored when BCLXL was |
| | al Que | ectopically overexpressed. When spheroid cultures were treated with ABT-737 |
| | C C Lange me Dan | or WEHI-539 compounds, CSCs were effectively sensitized toward oxaliplatin |
| | | and other chemotherapeutic agents. |
| | Animal experiment | |
| In Vivo | Applications: | |

Product Citations

1. Rose JC, Dieter EM, et al. "Examining RAS pathwayrewiring with a chemically inducible activator of RAS." Small GTPases. 2018 Apr 10:1-8.PMID:29634387

See more customer validations on www.apexbt.com.

References

1. Colak S, Zimberlin CD, Fessler E et al. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ. 2014 Jul;21(7):1170-7.

Caution

FOR RESEARCH PURPOSES ONLY.

APEXE

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com 7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

2 | www.apexbt.com



